contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-physitrack-q1-interview-growth-pivot-starts-here-rtm-to-lead-the-us-offensive

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Physitrack operates in the healthcare sector and specializes in physiotherapy. The product portfolio includes digital healthcare offerings for companies via SaaS solutions. In addition to the main business, personal service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe and North America. Physitrack was founded in 2012 and is headquartered in London.

Muita virallisia analyytikkotaloja ei taida olla Phystrackia seurannut.  Pari ruotsalaista yksityistä / yritystä sijoittajaa kyllä löytyy:                   otanalytics.se              OTANALYTICS.SE - Physitrack    Investeringsfakta The story Tillväxtresan Lönsamhet Mot målen Återkommande intäkter Bolagsvärde Q&A med VD Analys Det senaste | Mina YouTube-klipp | OT Analytics sysslar med värdebaserad analys och bevakning av utvalda småbolag med hög...                                               Lind Research              Physitrack (PTRK): First US Deal Signals Physitrack's Enterprise Pivot Is...    Physitrack's first US enterprise deal is immaterial in size, less than 0.3% of Lifecare revenue, but the signal matters more than the dollars. An academic medical center is a credibility-conferring reference account, and this is the third...

Niinpä, on stabiilia. Onneksi kuitenkin pikkuhiljaa kellutaan eteenpäin. Saisi olla mielellään vähän vahvempia lukuja ennen USA listauksia. Ollaan muuten valuttu taas aika lähellä R Eyen bear keissiä: Physitrack - Redeye Ei taida enää olla muita analyytikkoja tämän kimpussa?

Stabiilia            storage.mfn.se              q1-2026-interim-report-v1.pdf                              Summary for the period First quarter: 1 January – 31 March 2026 Based on Alternative Key Performance Measures, the Company’s key financial highlights for the period are summarised below.  Constant currency revenue amounted to EUR 3.3m (EUR 3.1m), corresponding to 6 per cent year-on-year growth. Subscription revenue continued to represent the majority of Group revenue (96 per cent), reflecting the strength of the recurring SaaS model. Adjusted EBITDA decreased 3 per cent maintaining at EUR 1.1m (EUR 1.1m), corresponding to a margin of 34 per cent (36 per cent). Adjusted EBITDA less CapEx decreases to EUR 0.3m (EUR 0.5m). Operating cash flow from continuing operations maintained at a relatively consistent level EUR 0.9m (EUR 1.0m). Free cash flow from continuing operations remained positive at EUR 0.1m (EUR 0.2m), maintaining 6 consecutive quarters of positive free cash flow.   Mielenkiintoinen poiminta, listaus US OTC markkinalle   A further development is our ongoing review of a potential quotation on the OTCQX Best Market in the United States. This could enhance access to US investors without affecting our Nasdaq First North Premier listing or involving a capital raise, supporting our continued expansion in North America.

Luvat saatu lainoittajalta ohjelman aloittamiseen  Physitrack PLC receives lender consent for share buyback program Physitrack PLC (Nasdaq First North: PTRK) (“Physitrack” or the “Company”) today announces that it has received the necessary consent from its banking partner to proceed with its previously announced share buyback program (the “SBB”), removing the final material condition to implementation. The SBB will be subject to an annual cap and will incorporate standard governance controls, including pause triggers and resumption conditions appropriate for a program of this nature. All repurchases will be conducted in accordance with the safe harbour provisions of EU Market Abuse Regulation (MAR) Article 5 and Nasdaq First North Premier Growth Market requirements. Henrik Molin, CEO and co-founder, commented: “Receiving bank approval is an important milestone. All material conditions to the program are now in place and we look forward to updating shareholders further in due course as we appoint a broker for the execution of the program.”

US markkinalta pää auki   Arvoltaan ei toki niin merkittävä, mutta signaaliarvo jatkoa ajatellen erittäin hyvä.  Physitrack signs Agreement with New York-based Academic Medical Center Physitrack PLC (Nasdaq First North Premier: PTRK) — New Commercial Agreement Generates $100,556 in Total Contract Value and $31,897 in Annual Recurring Revenue with major North American Customer. NEW YORK, United States, and LONDON, United Kingdom, March 30, 2026 Physitrack today announced a new commercial agreement with a New York state-based academic medical center to deliver the Physitrack platform. The agreement is valued at $100,556 in total contract value and $31,897 in annual recurring subscription revenue, with revenue recognition expected to commence in Q2 2026. Subsequent phases of the agreement may include expanded scope and additional user licenses, with the potential to generate additional recurring revenue. Under the agreement, Physitrack will provide its digital rehabilitation and clinical exercise prescription platform to 190 clinician users, enabling the customer to:  Improve access to rehabilitation care and remote patient monitoring across clinical teams Scale digital home exercise programme delivery and patient education through a single integrated platform Enhance clinical outcomes tracking and patient engagement through integrated telehealth capabilities

Wellness puolen diilejä olisi enemmän toiveissa, että sen kilpailukykyisyys ja tarve tulisi todistettua. Kelpaa tämäkin kyllä sitä odotellessa   Physitrack announces agreement with leading Swiss healthcare organisation Physitrack PLC (Nasdaq First North Premier: PTRK) has reached an agreement with a major Swiss Health Care organisation. The deal is worth 149,985 CHF (approximately 156,000 EUR), equivalent to 37,497 CHF (approximately 39,000 EUR) in annual recurring subscription revenue (ARR)             storage.mfn.se              physitrack-announces-agreement-with-leading-swiss-healthcare-organisation.pdf

Physitrack aloittaa omien osakkeiden ostot, kun kassavirta on vihdoin kunnossa ja arvostus alhaalla    Physitrack PLC announces intention to implement share buyback program Physitrack’s Board of Directors has approved the intention to implement a share buyback program (the “SBB”), subject to lender consent and prevailing market conditions. London, February 20. 2026 Physitrack PLC (Nasdaq First North: PTRK) (“Physitrack” or the “Company”) today announces that its Board of Directors has approved the intention to implement a share buyback program (the “SBB”), subject to lender consent and prevailing market conditions. The Board believes that, following the Group’s strengthened profitability, improved margin profile and sustained positive free cash flow, it is appropriate to establish a framework that enhances capital flexibility and supports long-term shareholder value creation. The Company intends to utilise the existing shareholder authorisation granted at the Annual General Meeting to repurchase up to 10 per cent of the Company’s issued share capital. Any repurchases would be funded from operating cash flow and distributable reserves and would not involve drawings under the Company’s revolving credit facility. The SBB provides the Company with flexibility in capital allocation. Repurchased shares may be cancelled to reduce the number of shares outstanding or held in treasury for potential future use, including possible share-based incentive arrangements. No share-based incentive plan has been approved at this time. Henrik Molin, CEO and co-founder, commented:  “Physitrack exits 2025 with materially improved cash generation, stronger margins and a more focused operating model. Establishing a share buyback framework reflects the Board’s confidence in the business and its commitment to disciplined capital allocation. We view buybacks, like dividends, as a legitimate shareholder value tool. This program provides flexibility to optimise our capital structure while continuing to invest in growth.” Implementation of the program remains subject to approval from the Company’s banking partner. The Board does not currently anticipate any impediment to obtaining such approval. The timing, size and execution of any repurchases will remain at the discretion of the Board and will be conducted in accordance with the EU Market Abuse Regulation (MAR), applicable safe harbour rules and Nasdaq First North Premier Growth Market requirements. No share repurchases have been made as of the date of this announcement. Further updates will be provided in accordance with applicable disclosure requirements

Physitrack

Redeye’s analyst just published an interview with Physitrack.Click here to watch the interviewMake sure to add Physitrack to your Watchlist at Redeye and our analysts will notify you if anything...

<div class="mfn-body"><p>Redeye’s analyst just published an interview with Physitrack.</p><p><strong><a href="https://www.redeye.se/research/1161319/physitrack-q1-interview-growth-pivot-starts-here-rtm-to-lead-the-us-offensive?utm_source=MFN&amp;utm_medium=pmcour" rel="noopener">Click here to watch the interview</a></strong></p><p>Make sure to add Physitrack to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies.</p><p>This is a press release from Redeye - Research Powered Investment Banking.&nbsp;<a href="http://www.redeye.se/" rel="noopener">www.redeye.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/caedcb6e-5482-4081-b5af-a03a568315e0/physitrack-q1-interview-growth-pivot-starts-here-rtm-to-lead-the-us-offensive.pdf" rel="noopener">Physitrack (Q1 Interview): Growth pivot starts here; RTM to lead the US offensive</a></p></div>